Vir Biotechnology CSO Herbert (Skip) Virgin steps down effective August 31, 2022

Vir Biotechnology, Inc.

Herbert (Skip) Virgin, M.D., Ph.D., notified the company on July 11, 2022.
He will resign as EVP, Research and Chief Scientific Officer effective August 31, 2022.
No replacement or interim appointment has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Herbert (Skip) Virgin

Executive Vice President, Research and Chief Scientific Officer

VIR · Vir Biotechnology, Inc.

Effective: 2022-08-31
Filed: July 14, 2022, 7:59 PM ET

On July 11, 2022, Herbert (Skip) Virgin, M.D., Ph.D., notified Vir Biotechnology, Inc. (the “Company”) that he will step down as Executive Vice President, Research and Chief Scientific Officer of the Company effective August 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Herbert (Skip) Virgin resigned as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, Inc..

Action: resigned
Role: Executive Vice President, Research and Chief Scientific Officer

Exact text from the filing

On July 11, 2022, Herbert (Skip) Virgin, M.D., Ph.D., notified Vir Biotechnology, Inc. (the “Company”) that he will step down as Executive Vice President, Research and Chief Scientific Officer of the Company effective August 31, 2022.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-193370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.